Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
ADHD Attention Deficit and Hyperactivity Disorders
Published in: ADHD Attention Deficit and Hyperactivity Disorders 4/2011

01-12-2011 | Original Article

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

Authors: Adel Gabriel, Claudio Violato

Published in: ADHD Attention Deficit and Hyperactivity Disorders | Issue 4/2011

Login to get access

Abstract

To examine changes in partially responsive anxiety symptoms utilizing adjunctive treatment with atomoxetine in the treatment of adult ADHD patients with comorbid partially responsive anxiety symptoms. Consenting adult patients (n = 29) with confirmed diagnosis of generalized anxiety and comorbid attention deficit hyperactivity disorder (ADHD) participated in this open-label study. All patients had significant comorbid anxiety symptoms (HAM-A > 7) and failed to respond to 8-week trials of selective serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs). All patients were treated with atomoxetine as adjunctive to SSRIs or to SNRIs and were followed for at least 12 weeks. The primary outcome measure was the Clinical Global Impression severity subscale. Other scales included the Hamilton Anxiety Scale (HAM-A), the adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist, and Sheehan’s Disability Scale. Baseline measures prior to the treatment with atomoxetine were compared to those at 4, 8, and at 12 weeks of treatment. Monitoring for pulse, blood pressure, and weight changes was carried out at baseline and at end point. Twenty-seven patients (93%) completed this open-label study. There was significant resolution of symptoms of all outcome measures, including the symptoms of anxiety, as shown by changes from baseline in HAM-A, ASRS-v1.1, and CGI at 12 weeks (P < .001). Also, there was significant reduction in the disability score at 12 weeks. Patients completed the study, tolerated the adjunctive treatment, and there were no significant cardiovascular or weight changes. Two patients withdrew from the study during the first 4 weeks of treatment due to side effects. Atomoxetine can be used as an adjunctive treatment in adult patients with ADHD and comorbid partially responsive anxiety symptoms.
Literature
Adler LA, Reingold LS, Morrill MS, Wilens TE (2006a) Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 8(5):409–415PubMedCrossRef
Adler L, Sutton V, Moore R, Dietrich A, Reimherr F, Sangal R, Saylor K, Secnik K, Kelsey D, Allen A (2006b) Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 26(6):648–652PubMedCrossRef
Adler L, Spencer T, Farone S, Kessler R, Howes M, Beiderman J, Secnik C (2006c) Validity of pilot adult ADHD self report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry 18(3):145–148PubMedCrossRef
Adler L, Spencer T, Williams D, Moore R, Michelson D (2008a) Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 12(3):248–253PubMedCrossRef
Adler L, Spencer T, Levine L, Ramsey J, Tamura R, Kelsey D, Ball S, Allen AJ, Biederman J (2008b) Functional outcomes in the treatment of adults with ADHD. J Atten Disord 11(6):720–727PubMedCrossRef
Adler L, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz P, Williams D, Kelsey D (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 29(1):44–50PubMedCrossRef
Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson J, den Boer J, Fineberg N, Knapp M, Scott J, Wittchen H (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567–596PubMedCrossRef
Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67(4):524–540PubMedCrossRef
Brown R, Amler R, Freeman W (2005) Treatment of attention deficit hyperactivity disorder: overview of evidence. Paediatrics 115:749–757CrossRef
CADDRA: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (2008) Canadian ADHD practice guidelines. CADDRA, Toronto
Christman AK, Fermo JD, Markowitz JS (2004) Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 24(8):1020–1036PubMedCrossRef
Durell T, Adler L, Leibowitz M, Rubin R, Qiao M, Hollandbeck M, Deldar A, Glaser P, Kronenberger W (2010) An 8-week, open label extension period study of atomoxetine in adults with attention–deficit/hyperactivity disorder and comorbid social anxiety disorder. J ADHD Relat Disord 3:36–52
Gabriel A (2010) The mixed amphetamine salt extended release (Adderall XR, MAX–XR) as an adjunctive to SSRIs or SNRIs in the treatment of adult patients with comorbid partially responsive generalized anxiety: an open label study. ADHD Atten Def Hyp Disord 2010(2):87–92CrossRef
Gadde K, Yonish G, Wagner HR, Foust M, Allison D (2006) Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond) 30(7):1138–1142CrossRef
Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C (2007) Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 46(9):1119–1127PubMedCrossRef
Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Rockville
Henning E, Turk C, Mennin D, Fresco D, Heimberg R (2007) Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24:342–349PubMedCrossRef
Kessler R, Brandenburg N, Lane M, Roy-Byrne P, Stang P, Stein D, Wittchen H (2005) Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35:1073–1082PubMedCrossRef
Kessler R, Adler L, Barkley R, Biederman J, Conners C, Demler O, Faraone S, Greenhill L, Howes M, Secnik K, Spencer T, Ustun T, Walters E, Zaslavsky A (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163(4):716–723PubMedCrossRef
Kratochvil C, Vaughan B, Harrington M, Burke W (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 4:1165–1174PubMedCrossRef
Kratochvil C, Newcorn J, Arnold L, Duesenberg D, Emslie G, Quintana H, Sarkis E, Wagner KD, Gao H, Michelson D, Biederman J (2005) Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44(9):915–924PubMedCrossRef
Matza LS, Johnston JA, Faries DE, Malley KG, Brod M (2007) Responsiveness of the adult attention-deficit/hyperactivity disorder quality of life scale (AAQoL). Qual Life Res 16(9):1511–1520 (Epub 2007 Sep 12)PubMedCrossRef
McGough J, Smalley S, McCracken J, Yang M, Del’Homme M, Lynn D, Loo S (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162:1621–1627PubMedCrossRef
McIntyre RS, Konarski JZ, Mancini DA, Fulton KA, Parikh SV, Grigoriadis S, Grupp LA, Bakish D, Filteau MJ, Gorman C, Nemeroff CB, Kennedy SH (2005) Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ 173(11):1327–1334PubMedCrossRef
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120PubMedCrossRef
Ravindran L, Kim D, Letamendi A, Stein M (2009) A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 29(6):561–564PubMedCrossRef
Ruscio A, Chiu W, Roy-Byrne P, Stang P, Stein D, Wittchen H, Kessler R (2007) Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 21:662–676PubMedCrossRef
Schweizer E (1995) Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Psychiatr Clin North Am 18:843–857PubMed
Scott N, Ripperger-Suhler J, Rajab M, Kjar D (2010) Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 20(3):197PubMedCrossRef
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33
Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205–222PubMedCrossRef
Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155(5):693–695PubMed
Spencer T, Faraone S, Michelson D, Adler L, Reimherr F, Glatt S, Biederman J (2006) Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67(3):415–420PubMedCrossRef
Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28(11):1892–1908PubMedCrossRef
Van Brunt D, Johnston J, Ye W, Pohl G, O’Hara N (2006) Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm 12(3):230–238PubMed
Vaughan B, Fegert J, Kratochvil CJ (2009) Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 10(4):669–676PubMedCrossRef
Wade A, Despiegel N, Heldbo Reines E (2006) Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 18:83–89PubMedCrossRef
Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26(10):729–740PubMedCrossRef
Wilens T, Biederman J, Faraone S, Martelon M, Westerberg D, Spencer T (2009) Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry 70:1557–1562PubMedCrossRef
Metadata
Title
Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study
Authors
Adel Gabriel
Claudio Violato
Publication date
01-12-2011
Publisher
Springer Vienna
Published in
ADHD Attention Deficit and Hyperactivity Disorders / Issue 4/2011
Print ISSN: 1866-6116
Electronic ISSN: 1866-6647
DOI
https://doi.org/10.1007/s12402-011-0063-1

Other articles of this Issue 4/2011

ADHD Attention Deficit and Hyperactivity Disorders 4/2011 Go to the issue

Original Article

Effects of DSP4 and methylphenidate on spatial memory performance in rats

Original Article

Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials

Original Article

An exploration of the associations of pregnancy and perinatal features with cytokines and tryptophan/kynurenine metabolism in children with attention-deficit hyperactivity disorder (ADHD)

Original Article

The screens culture: impact on ADHD